• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ICH Plans Drug Development Guideline to Boost Trial Design

ICH Plans Drug Development Guideline to Boost Trial Design

May 9, 2022

A planned International Council for Harmonization (ICH) guideline on model-informed drug development (MIDD) will help optimize clinical trial designs, according to ICH, which estimates development of the guideline will be complete in three to four years.

The FDA and other regulators have signaled increased interest in MIDD, an approach that involves creating biological and statistical models from preclinical and clinical data and using these models to develop trial designs. The FDA is currently running a pilot program to spur the development of these models and evaluate their application to trial designs.

Such models can help optimize time and resources in early-phase trials and inform later-phase trials, ICH said in its roadmap to MIDD guideline development.

The approach currently lacks common documentation standards, consistent expectations for model assessments and understanding of terminologies, making it harder to efficiently evaluate model-based submissions, including the quality of the data involved, according to the ICH discussion group charged with developing the guideline.

The discussion group also recommended ICH revise its guideline on Dose Response Studies (E4) to incorporate principles developed for the MIDD guideline.

ICH said it may consider developing additional guidance on MIDD beyond the general principles in approximately three years.

Development and adoption of a new ICH guideline is a five-step process — from initial discussions and draft to final acceptance by ICH member countries — that can take up to a decade to complete.

Read the MIDD roadmap here: https://bit.ly/3yi1HAS.

 

To view more CenterWatch Weekly stories, click here.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing